Corium International, Inc.

Company Summary

A commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products. Prior to its IPO, Corium was a portfolio company of Essex Woodlands and Aphelion Capital.

Transaction Overview

Significance of the Transaction

The Notes financing permits the Company to expand its specialty contract manufacturing capabilities and broaden existing strategic partnerships with global generics manufacturers The IPO allows the Company to pursue advanced clinical development of its proprietary CorPlex and MicroCor transdermal product candidates, in addition to providing attractive liquidity to shareholders

Healthios Role

If you would like to learn more information about this transaction contact us below.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Corium International, Inc.
$52,000,000 Initial Public Offering
The undersigned acted as strategic advisor to Corium International
Read More